Johnston G D, Finch M B, McNeill J A, Shanks R G
Br J Clin Pharmacol. 1985 Nov;20(5):507-10. doi: 10.1111/j.1365-2125.1985.tb05109.x.
In a placebo controlled open study in six healthy male volunteers (+)-sotalol in the dose range 0.125 mg kg-1-2.0 mg kg-1 intravenously, was found to have little or no beta-adrenoceptor blocking activity in comparison to the racemic mixture (+/-)-sotalol. The repolarization effects of (+)- and (+/-)-sotalol on the QTc interval however were comparable over the same dose range. The beta-adrenoceptor blocking activity and repolarization effects of sotalol appear to be unrelated.
在一项针对6名健康男性志愿者的安慰剂对照开放研究中,静脉注射剂量范围为0.125毫克/千克至2.0毫克/千克的(+)-索他洛尔,与消旋混合物(+/-)-索他洛尔相比,几乎没有或没有β-肾上腺素能受体阻断活性。然而,在相同剂量范围内,(+)-和(+/-)-索他洛尔对QTc间期的复极作用相当。索他洛尔的β-肾上腺素能受体阻断活性和复极作用似乎没有关联。